Thermo Fisher Scientific (TMO) Cost of Revenue (2009 - 2026)

Thermo Fisher Scientific has disclosed Cost of Revenue across 18 years of filings, most recently posting $3.3 billion for Q1 2026.

• Quarterly Cost of Revenue rose 4.35% year-over-year to $3.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 billion (up 1.66% YoY) and the FY2025 annual result came in at $12.9 billion, up 2.05% from the prior year.
• Cost of Revenue climbed to $3.3 billion in Q1 2026, from $3.2 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $3.7 billion in Q4 2023 and troughed at $2.9 billion in Q4 2022.
• A 5-year average of $3.3 billion and a median of $3.2 billion in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 14305.0% — and 2023, when it slipped 9.06%.
• Tracing TMO's Cost of Revenue over 5 years: stood at $3.7 billion in 2022, then advanced by 1.39% to $3.7 billion in 2023, then dropped by 7.18% to $3.5 billion in 2024, then dropped by 6.78% to $3.2 billion in 2025, then advanced by 0.96% to $3.3 billion in 2026.
• Business Quant data shows TMO's Cost of Revenue at $3.3 billion in Q1 2026, $3.2 billion in Q4 2025, and $3.3 billion in Q3 2025.